These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39168631)

  • 1. Infusion Reactions in HER2-Positive Gastric Cancer: Switching from Trastuzumab to Its Biosimilar.
    Abe T; Sagara A; Suzuki T; Okada D; Matsuzaka K; Nakayama T
    Biol Pharm Bull; 2024; 47(8):1452-1455. PubMed ID: 39168631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
    Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABP 980: A Trastuzumab Biosimilar.
    Dhillon S
    BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study.
    Saito Y; Tamaki S; Hasegawa H; Takahashi K; Tokutome A; Takekuma Y; Yamashita H; Komatsu Y; Sugawara M
    Biol Pharm Bull; 2021; 44(4):474-477. PubMed ID: 33790098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PF-05280014: A Trastuzumab Biosimilar.
    Paik J
    BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SB3 (Ontruzant
    Lamb YN
    BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
    Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
    Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
    Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
    Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study.
    Mohan MVTK; Prajapati A; Kothari R; Mandal S; Rao Srikanth R; Nagarkar R; Khane S; Santa A; Dadke D
    Clin Drug Investig; 2024 Jul; 44(7):513-525. PubMed ID: 38937403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
    Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
    Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN
    Abe T; Sagara A; Okada D; Matsuzaka K
    Mol Clin Oncol; 2023 May; 18(5):41. PubMed ID: 37035469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
    Jeon C; Kang SH; Kim SB; Paik NS; Lee I; Kim SK; Kim EY; Son GS; Yoo YB; Lee KH; Shin J; Ju S; Jang H; Park MH
    Oncology; 2024; 102(6):465-475. PubMed ID: 37899039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
    Esteva FJ; Saeki T; Kim H; Stebbing J
    Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
    Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y
    Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
    Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
    Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
    AbdulHameed Saeed V; Mohammed NAK
    Arch Razi Inst; 2023 Jun; 78(3):981-988. PubMed ID: 38028843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
    Oh SY; Lee S; Huh SJ; Lee J; Kim ST; Park SH; Lim HY; Kang WK; Kang BW; Kim JG; Lee HJ; Kim JH; Kang JH; Kim H
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):501-508. PubMed ID: 30535535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biosimilars in oncology. Focus on SB3 studies.].
    Del Re M; Del Mastro L
    Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.